ArticleProstate cancer and prostatic diseases2021
Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.
Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Inheritance patterns of lower urinary tract symptoms in adults: a systematic review.BJU international · 2025Pooled it
- Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men.Journal of global health · 2026Article
- Sport, genetic susceptibility, and the risk of benign prostatic hyperplasia: a large prospective cohort study.World journal of urology · 2026Article
- Predicting benign prostatic hyperplasia risks: model development and external validation based on three cohorts.Global health research and policy · 2025Article
- Network pharmacology and experimental validation to explore the pharmacological mechanism of saw palmetto and its core ingredients in benign prostatic hyperplasia treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Genetic Predisposition to Benign Prostatic Hyperplasia: Where Do We Stand?European urology open science · 2024Review
- Clinical biomarker-based biological aging and risk of benign prostatic hyperplasia: A large prospective cohort study.Aging medicine (Milton (N.S.W)) · 2024Article
- Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBenign prostatic hyperplasia (BPH) is common noncancerous prostate enlargement, which is usually associated with lower urinary tract symptoms (LUTS) and can lead to complex urinary, bladder, or kidney diseases. The majority of elderly men will be affected by BPH as age increases.
methodsHere, we conducted a genome-wide association study (GWAS) of BPH using 1942 cases and 4730 controls from the Electronic Medical Records and Genomics network (eMERGE) as discovery cohort. We then used 5109 cases and 161,911 controls from UK Biobank as validation cohort.
resultsThis GWAS discovered 35 genome-wide significant variants (P < 5 × 10
conclusionsOur results suggest that genetic variants identified from BPH GWAS can identify pharmacologic targets for BPH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.